Drug Profile
Molnupiravir - Emory University/Georgia State University/Merck & Co/Ridgeback Biotherapeutics
Alternative Names: EIDD-2801; LAGEVRIO; MK-4482; Molxvir; MovforLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Emory University; Georgia State University
- Developer Emory University; Hetero Labs; Merck & Co; Merck Sharp & Dohme; Ridgeback Biotherapeutics
- Class Antivirals; Esters; Hydroxylamines; Pyrimidinones; Ribonucleosides; Small molecules
- Mechanism of Action Virus replication inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
- Phase II Respiratory syncytial virus infections
- Phase I Influenza virus infections; Renal failure
- Preclinical Chikungunya virus infections; Eastern equine encephalomyelitis; Ebola virus infections; Middle East respiratory syndrome coronavirus; Severe acute respiratory syndrome; Venezuelan equine encephalomyelitis
Most Recent Events
- 21 Aug 2023 Phase-I clinical trials in Influenza virus infections (In volunteers) in United Kingdom (PO) (NCT05818124)
- 21 Jun 2023 Regulatory submission withdrawn for COVID-2019 infections in European Union (PO)
- 21 Jun 2023 Merck Sharp & Dohme withdraws a marketing authorisation application for molnupiravir for COVID-19 infections in the European Union